KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Equity Ratio (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Equity Ratio for 15 consecutive years, with 0.19 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 90.82% year-over-year to 0.19, compared with a TTM value of 0.19 through Dec 2025, up 90.82%, and an annual FY2025 reading of 0.19, up 90.82% over the prior year.
  • Equity Ratio was 0.19 for Q4 2025 at Travere Therapeutics, up from 0.14 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.47 in Q1 2021 and bottomed at 0.06 in Q3 2024.
  • Average Equity Ratio over 5 years is 0.19, with a median of 0.16 recorded in 2023.
  • The sharpest move saw Equity Ratio crashed 83.62% in 2022, then soared 326.23% in 2025.
  • Year by year, Equity Ratio stood at 0.39 in 2021, then plummeted by 83.62% to 0.06 in 2022, then soared by 299.52% to 0.25 in 2023, then crashed by 60.94% to 0.1 in 2024, then skyrocketed by 90.82% to 0.19 in 2025.
  • Business Quant data shows Equity Ratio for TVTX at 0.19 in Q4 2025, 0.14 in Q3 2025, and 0.06 in Q2 2025.